N/A
N=410
Description of the Population With Genitourinary Tumors and COVID-19
Covid19 · Genito Urinary Cancer
Bottom Line
View on ClinicalTrials.gov: NCT04578132 ↗Enrolled (actual)
410
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcome: Primary: Age at Baseline — 70 years
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Spanish Oncology Genito-Urinary Group
- Primary completion
- Nov 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Age at Baseline |
70 | — |
| PRIMARY Frequency of Complications of COVID-19 Intercurrent Infection |
73; 5; 136; 3; 191 | — |
| PRIMARY Frequency of Complications of COVID-19 Infection (Pneumonia) Stratified by Treatment |
51; 36; 181; 140 | — |
| PRIMARY Frequency of Complications of COVID-19 Infection in Patients With Genitourinary Cancer Stratified by Anti-androgenic Oncological Treatment |
59; 55; 173; 120; 1 | — |
| PRIMARY Frequency of Complications of COVID-19 Infection Stratified by Treatment (Immunotherapy vs no Immunotherapy) |
45; 31; 11; 146; 113; 62 | — |
| PRIMARY Frequency of Adverse Events Related to Immunotherapy Targeted to Cancer (Classified by Type and Severity) |
1; 1; 1; 1; 1; 3 | — |
| SECONDARY COVID-19 Mortality Rate in Patients With Genitourinary Cancer |
137; 80; 191 | — |
| SECONDARY COVID-19 Complication Rate in Patients With Genitourinary Cancer |
73; 5; 136; 3; 191 | — |
| SECONDARY Asymptomatic Rate |
308; 100 | — |
| SECONDARY Asymptomatic Rate in Renal Cancer |
63; 27 | — |
| SECONDARY Asymptomatic Rate in Urothelial Cancer |
32; 96 | — |
| SECONDARY Asymptomatic Rate in Prostate Cancer |
33; 133 | — |
| SECONDARY Asymptomatic Rate in Testicular Cancer |
6; 15 | — |
| SECONDARY Frequency of Delays/Modifications on Cancer Treatment Schedule |
38; 108; 24; 156 | — |
| SECONDARY Progression Free Survival in Patients With Genitourinary Tumors That Suffered COVID-19, Patients With a First Line Treatment Ongoing at the Moment of COVID Infection |
93.26; 80.13; 121.94 | — |
| SECONDARY Overall Survival in Patients With Genitourinary Tumors That Suffered COVID-19 |
18.36; 7.03; 11.49; 24.37 | — |
Summary
The identification of patients with genitourinary tumors who suffer from the infection by the Serious Acute Respiratory Syndrome Corona-Virus 2 (SARS-CoV-2) virus can represent multiple benefits both for themselves and for health professionals and the health system itself. We would be able to know more precisely the clinical evolution of these type of patient, to know their prognosis and being capable to select the most appropriate treatment modality for future pandemics.
SOGUG-COVID is an observational prospective-retrospective trial purely epidemiological, that aims to describe the population with genitourinary tumors (urothelial cancer, prostate cancer, testicular cancer and kidney cancer) infected by COrona VIrus Disease 19 (COVID-19) treated in Spanish hospitals, learn about the clinical presentation, therapeutic evolution and prognosis of said intercurrent infectious process, as well as its possible relationship with different clinical and therapeutic factors.
Eligibility Criteria
Inclusion Criteria
- Patients ≥18 years old.
- Diagnosed with genitourinary cancer (urothelial, kidney, prostate and germ).
- COVID-19 infection prior to cancer treatment, during treatment, or after treatment.
- The COVID-19 infection must be confirmed by PCR or serology, regardless of whether or not the patient requires hospitalization for the infection, additionally, a clinical and / or radiological determination must be available in those patients who present symptoms.
Exclusion Criteria
- Not applicable
Data sourced from ClinicalTrials.gov (NCT04578132). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.